Logo

AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

Share this

AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

Shots:

  • The companies have signed an 18mos. supply agreement under a 3yrs. master supply and development agreement. Oxford Biomedica to receive $17.95M up front as a capacity reservation fee and expects to receive additional revenue of $41.89M + materials costs for the manufacturing of multiple large-scale batches of AZD1222 until the end of 2021
  • Oxford Biomedica will reserve capacity for ~3 manufacturing suites in the Oxbox- for an initial 18mos. period. The new GMP facility is suitable for manufacturing viral vectored vaccines and gene therapy vectors up to 1-000-liter scale.
  • The companies may extend the supply period for AZD1222 by a further 18mos. into 2022 and 2023 by mutual agreement. The agreement follows the supply agreement b/w the companies signed on May 28- 2020 for exclusively manufacture AZD1222 at 200L scale and associated process development

­ Ref: Oxford Biomedica | Image: Yahoo Sports

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions